ArticleBreast cancer research and treatment2016

Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.

Vakaramoko Diaby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.